Estadístiques de Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension
Visites totals
| views | |
|---|---|
| Pulmonary hypertension in interstitial lung disease: Clinical trial design and endpoints: A consensus statement from the Pulmonary Vascular Research Institute's Innovative Drug Development Initiative-Group 3 Pulmonary Hypertension | 23 |
Visites totals per mes
| views | |
|---|---|
| October 2024 | 0 |
| November 2024 | 2 |
| December 2024 | 1 |
| January 2025 | 0 |
| February 2025 | 0 |
| March 2025 | 0 |
| April 2025 | 0 |
Visites al fitxer
| views | |
|---|---|
| Nathan_pc_pulm.pdf | 29 |
| Nathan_pc_pulm.pdf(legacy) | 13 |
Vistes principals per país
| views | |
|---|---|
| United States | 13 |
| Australia | 4 |
| Argentina | 2 |
| Germany | 2 |
| Switzerland | 1 |
| Mongolia | 1 |
Visites principals per ciutat
| views | |
|---|---|
| Menlo Park | 3 |
| Mountain View | 3 |
| San Diego | 3 |
| Suipacha | 2 |
| Ashburn | 1 |
| Pinjarra | 1 |
| Sacramento | 1 |
| Sükhbaatar | 1 |
| Tuggen | 1 |